Lantox

2024: Entering the Russian market

In early July 2024, Binnopharm Group announced sales of a Chinese analogue of Botox called Lantox. To do this, the company bought the rights to sell the drug in Russia back in 2023

Lantox botulinum toxin is produced by the Chinese company Lanzhou Biotechnique Development (LBD). According to Nikolai Bespalov, RNC Pharma Development Director, the cost of rights to sell the drug could range from 4 to 9 million rubles. The management of Binnopharm Group expects that the potential sales of Lantox in Russia will reach 2-3 billion rubles. per year.

Unsplash

The emergence of a new drug on the Russian market is associated with the departure of the manufacturer of the original Botox - the Irish company Allergan, as well as interruptions in the supply of botulinum toxins from another Western manufacturer - Merz. These changes led to a significant restructuring of the aesthetic medicine market in Russia.

According to RNC Pharma, in the first five months of 2024, 579.3 thousand packages of botulinum toxins were sold in Russia for a total of 5.7 billion rubles. The market leader is currently Dysport from the French company Ipsen with a share of 34.5%, followed by the Russian Relatox from Microgen with a share of about 29%.

Yulia Frangulova, co-founder of the SRO "National Association of Clinics of Aesthetic Medicine" and general director of the Linline network of clinics, believes that the drug will be able to occupy a significant market share only due to a significant price reduction.

In addition to botulinum toxin, Binnopharm Group plans to expand its presence in the aesthetic medicine market. The company plans to produce collagen-based fillers for contour surgery and develop a generic Emla anesthetic cream for cosmetic surgery.^[1]

Notes